Market Risers: AstraZeneca, Aviva, Berkeley Group Holdings, Capital Drilling

Capital Drilling
[shareaholic app="share_buttons" id_name="post_below_content"]

Shares in AstraZeneca EPIC code: LON:AZN has stepped up 1.34% or 96 points during the course of today’s session so far. Investors have remained positive throughout the session. Range high for the period has seen 7324 while the low for the session was 7154.1. The total volume of shares exchanged through this period comes to 720,062 with the daily average traded share volume around 2,319,439. The 52 week high for the shares is 7583 equating to 413 points different to the previous business close and a 52 week low sitting at 5312 a difference of some 1858 points. AstraZeneca has a 20 SMA of 7216.87 and now a 50 day simple moving average now of 7137.31. The current market capitalisation is £95,321.41m at the time of this report. The share price is in Great British pence. Mcap is measured in GBP. This article was written with the last trade for AstraZeneca being recorded at Tuesday, September 24, 2019 at 12:57:02 PM GMT with the stock price trading at 7266 GBX.

The stock price for Aviva company symbol: LON:AV has climbed 1.52% or 5.9 points throughout the session so far. Traders have remained optimistic throughout the session. The high for the period has peaked at 394.41 and a low of 390. The amount of shares exchanged has so far reached 3,021,437 with the daily average number around 12,515,008. The 52 week high is 498.5 amounting to 110.4 points difference from the previous days close and putting the 52 week low at 350 a difference of some 38.1 points. Aviva now has a 20 moving average of 376.91 and the 50 day moving average now of 389.37. The current market cap is £15,432.65m at the time of this report. The stock is traded in GBX. Mcap is measured in GBP. This article was written with the last trade for Aviva being recorded at Tuesday, September 24, 2019 at 12:57:10 PM GMT with the stock price trading at 394 GBX.

Shares of Berkeley Group Holdings with company EPIC: LON:BKG has gained 1.11% or 46 points during today’s session so far. Traders have so far held a positive outlook during the session. The period high has peaked at 4211 and a low of 4132. The total volume of shares exchanged so far has reached 127,032 with the daily average at 511,753. The 52 week high price for the shares is 4270 amounting to 116 points in difference to the previous days close of business and a 52 week low sitting at 3170 is a variance of 984 points. Berkeley Group Holdings now has a 20 simple moving average of 4044.49 and now a 50 day MA at 3944.54. The current market cap is £5,277.52m at the time of this report. The share price is in Great British pence. Mcap is measured in GBP. This article was written with the last trade for Berkeley Group Holdings being recorded at Tuesday, September 24, 2019 at 12:57:01 PM GMT with the stock price trading at 4200 GBX.

Shares of Capital Drilling ticker lookup code: LON:CAPD has increased 7.18% or 4.49 points during today’s session so far. Buyers have remained optimistic while the stock has been in play. Range high for the period so far is 66.99 and hitting a low of 62.16. The total volume of shares exchanged so far has reached 21,500 whilst the daily average number of shares exchanged is just 75,768. The stock 52 week high is 66.99 about 4.49 points difference from the previous days close and the 52 week low at 33.5 a difference of some 29 points. Capital Drilling Ltd now has a 20 moving average of 59.89 and a 50 day MA at 56.4. Market capitalisation is now £91.27m at the time of this report. The stock is traded in GBX. Mcap is measured in GBP. This article was written with the last trade for Capital Drilling Ltd being recorded at Tuesday, September 24, 2019 at 12:26:11 PM GMT with the stock price trading at 66.99 GBX.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
AstraZeneca Plc commits $3.5 billion to boost US research and manufacturing by 2026, creating jobs and expanding its innovation footprint.
AstraZeneca and Amgen's Tezspire shows promise in reducing nasal polyp size and congestion, offering hope for chronic rhinosinusitis patients.
AstraZeneca's Wainzua gains CHMP backing for EU approval in treating ATTRv-PN, marking a potential breakthrough with self-administered therapy.

Search

Search